🗞 News

Endoscopy is now available on Entrolytics. In the cloud, on-demand, and with in-built structured reporting (right next to other tests!!) 

The world’s first “full gut MRI exam” shows gastric symptoms in diabetic gastroparesis may actually be caused by the small bowel - Scroll to read more below 🤓 ⬇️

Motilent will be attending UEG Week from the 14th-17th of October at the Bella Center in Copenhagen. 

Motilent are proud to support our researchers going to UEG Week:

📢 The first ‘full gut exam’ with MRI links the source of diabetic gastric symptoms to the small bowel - not the stomach!

❗️50% of Diabetics report GI symptoms but it's still a poorly understood aspect of the disease that’s difficult to correctly diagnose and manage.

A group from Aalborg University Hospital, Denmark has found clear differences in the guts of diabetic patients compared to healthy controls, using an MRI whole-gut analysis technique examining the stomach, small bowel and colon (with Motilent’s technology 😁).

They found: 

  • The stomachs of patients varied little pre and post meal.
  • Diabetic patients had a significant reduction in small bowel motility after meal.
  • The colons of patients varied little pre and post meal.

🧐 So are the gastric symptoms the result of small bowel changes in behaviour rather than the stomach?

There are some implications of this work:

⚠️ It’s the first time a whole gut approach has been used to assess a complex disease state. 

⚠️ It’s one of the first uses of a provocation test (meal) at scale for practical MRI scanning.

⚠️ Raises more questions on drug development, symptom management and patient selection.

BUT... it demonstrates the power of MRI to look at structure and function across the whole gut and leverage powerful quantitative techniques.

🤓 Links to read more :

🔗 https://lnkd.in/ebbWCRVr

🔗 https://lnkd.in/egP8yFpd

🤔 Is developing a therapy for IBD getting harder? 30% of Crohns disease patients suffer from strictures.

Following on from our headline picture we have been highlighting the amazing work going on in IBD around strictures. New drugs are on the way, but getting the right patients on the right trials efficiently remains a challenge… Motilent is here to help!

💊There are no drugs to treat strictures

🚧 No pathway to characterise patient severity as an endpoint in trials

🏥 Most strictures would lead to perforation if not for surgery